There is a reported connection between racial color-blindness and clinical trial participation, with some outlets discussing its impact on cancer outcomes and others exploring its relationship to structural racism. The issue appears to be relevant to various medical conditions, including multiple sclerosis and breast cancer. Efforts to increase diversity in clinical trials are being undertaken, with some organizations providing funding for community-based projects to improve equitable outcomes.